Oral glucocorticoids for skin fibrosis in early diffuse systemic sclerosis: a target trial emulation study from the European Scleroderma Trials and Research group database

Systemic Sclerosis

Biological hallmarks of systemic sclerosis are present in the skin and serum of patients with Very Early Diagnosis of SSc (VEDOSS)

Rheumatology (Oxford)

Ross RL, Caballero-Ruiz B, Clarke EL, Kakkar V, Wasson CW, Mulipa P, De Lorenzis E, Merchant W, Di Donato S, Rindone A, Herrick AL, Denton CP, Riobo-Del Galdo NA, Del Galdo F

doi: 10.1093/rheumatology/keae698

Systemic SclerosisFurther Publications Immunology

COVID-19 vaccinations and infections among individuals with systemic sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study

Semin Arthritis Rheum

Lakin KS, Wu Y, Gordon JK, Kwakkenbos L, Carrier ME, Henry RS, Denton CP, Mouthon L, Spiera RF, Thombs BD, SPIN COVID-19 Vaccination Patient Advisory Team, SPIN Investigators

doi: 10.1016/j.semarthrit.2024.152453

Systemic Lupus Erythematosus

Efficacy and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events and Safety Outcomes in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population-based Target Trial Emulation

Arthritis Rheumatol

Ma KS, Lo JE, Kyttaris VC, Tsokos GC, Costenbader KH

doi: 10.1002/art.43037

Systemic Lupus ErythematosusSystemic Sclerosis

Menopausal hormone therapy and the risk of systemic lupus erythematosus and systemic sclerosis: a population-based nested case-control study

Rheumatology (Oxford)

Patasova K, Dehara M, Mantel Ä, Bixo M, Arkema E, Holmqvist M

doi: 10.1093/rheumatology/keaf004

Systemic Sclerosis

Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort Study

J Autoimmun

Chaigne B, Bense A, Aubourg F, Agard C, Allanore Y, Berezne A, Pugnet G, Hachulla E, Cottin V, Hot A, Dunogue B, Kanagaratnam A, Palat S, Lescoat A, Berthier S, Chatelus E, Rivière S, Launay D, Truchetet ME, Dinh-Xuan AT, Mouthon L, French Systemic Sclerosis Network

doi: 10.1016/j.jaut.2025.103391

Systemic Sclerosis

Systemic sclerosis and cancer in the UK: An epidemiological analysis using the Clinical Practice Research Datalink

Rheumatology (Oxford)

Pauling JD, McHugh NJ, McGrogan A

doi: 10.1093/rheumatology/keae433

Rheumatoid Arthritis

Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study

Lancet Rheumatol

Russell MD, Gibson M, Zuckerman B, Kumar K, Dubey S, Adas MA, Alveyn E, Patel S, Yang Z, Bechman K, Price E, Gallagher S, Cope AP, Norton S, Galloway JB

doi: 10.1016/S2665-9913(24)00221-2

Systemic Sclerosis

Rituximab retention rate in systemic sclerosis: a long term real-life multicenter study

Rheumatology (Oxford)

De Luca G, De Lorenzis E, Campochiaro C, Cacciapaglia F, Del Papa N, Zanatta E, Airò P, Lazzaroni MG, Giuggioli D, De Santis M, Alonzi G, Stano S, Binda M, Moccaldi B, Tonutti A, Cavalli S, Batani V, Natalello G, Iannone F, D'Agostino MA, Dagna L, Matucci-Cerinic M, Bosello SL

doi: 10.1093/rheumatology/keae280

Further Publications Immunology

Effectiveness of a symptom-clinic intervention delivered by general practitioners with an extended role for people with multiple and persistent physical symptoms in England: the Multiple Symptoms Study 3 pragmatic, multicentre, parallel-group, individually randomised controlled trial

Lancet

Burton C, Mooney C, Sutton L, White D, Dawson J, Neilson AR, Rowlands G, Thomas S, Horspool M, Fryer K, Greco M, Sanders T, Thomas RE, Cooper C, Turton E, Waheed W, Woodward J, Mallender E, Deary V

doi: 10.1016/S0140-6736(24)00700-1

Related content

Biological hallmarks of systemic sclerosis are present in the skin and serum of patients with Very Early Diagnosis of SSc (VEDOSS)

COVID-19 vaccinations and infections among individuals with systemic sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study

Efficacy and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events and Safety Outcomes in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population-based Target Trial Emulation

Menopausal hormone therapy and the risk of systemic lupus erythematosus and systemic sclerosis: a population-based nested case-control study

Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort Study

Systemic sclerosis and cancer in the UK: An epidemiological analysis using the Clinical Practice Research Datalink

Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study

Rituximab retention rate in systemic sclerosis: a long term real-life multicenter study

Effectiveness of a symptom-clinic intervention delivered by general practitioners with an extended role for people with multiple and persistent physical symptoms in England: the Multiple Symptoms Study 3 pragmatic, multicentre, parallel-group, individually randomised controlled trial